Global Solid Tumor Therapeutics Market Analysis By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy, Tyrosine kinase inhibitors, Proteasome inhibitor, Hedgehog pathway inhibitor, Others), By Route of Administration (Oral, Parenteral, Others), By End-Users (Hospitals, Specialty Clinics, Homecare, Others, Distribution Channel) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033
- Published date: Feb 2024
- Report ID: 135794
- Number of Pages: 369
- Format:
-
-
- 1. Executive Summary
- 1.1. Definition
- 1.2. Market Snapshot
- 1.3. Market Overview
- 1.4. Segment Overview
- 1.5. Regional Overview
- 1.6. Competitive Landscape
- 1.7. Taxonomy
- 2. Global Market Overview
- 2.1. Global Market Insights and Industry Overview
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunities
- 2.2.4. Key Solid Tumor Therapeutics Market Trends
- 2.3. Regulatory Framework
- 2.4. Opportunity Map Analysis
- 2.5. Opportunity Orbits
- 2.6. PESTLE Analysis
- 2.7. PORTER’S Five Force Analysis
- 2.8. Drivers & Restraints Impact Analysis
- 2.9. Value Chain Analysis
- 2.9.1. List of Raw Materials Suppliers
- 2.9.2. List of Solid Tumor Therapeutics Manufacturers
- 2.9.3. List of Dealer/Distributors
- 2.10. Regional Market Share and BPS Analysis
- 2.11. Impact of Macro-economic Factors/Geopolitical Factors
- 3. Global Solid Tumor Therapeutics Market Analysis and Forecast, By Segment, 2019-2033
- 3.1. Key Findings
- 3.2. Global Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Therapy Type, 2019-2033
- 3.3. Global Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- 3.3.1. Chemotherapy
- 3.3.1.1. Insights
- 3.3.1.2. Key Takeaways
- 3.3.2. Immunotherapy
- 3.3.2.1. Insights
- 3.3.2.2. Key Takeaways
- 3.3.3. Targeted Therapy
- 3.3.3.1. Insights
- 3.3.3.2. Key Takeaways
- 3.3.4. Tyrosine kinase inhibitors
- 3.3.4.1. Insights
- 3.3.4.2. Key Takeaways
- 3.3.5. Proteasome Inhibitor
- 3.3.5.1. Insights
- 3.3.5.2. Key Takeaways
- 3.3.6. Hedgehog Pathway Inhibitor
- 3.3.6.1. Insights
- 3.3.6.2. Key Takeaways
- 3.3.7. Others
- 3.3.7.1. Insights
- 3.3.7.2. Key Takeaways
- 3.3.1. Chemotherapy
- 3.4. Global Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, Route of Administration, 2019-2033
- 3.5. Global Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- 3.5.1. Oral
- 3.5.1.1. Insights
- 3.5.1.2. Key Takeaways
- 3.5.2. Parenteral
- 3.5.2.1. Insights
- 3.5.2.2. Key Takeaways
- 3.5.3. Others
- 3.5.3.1. Insights
- 3.5.3.2. Key Takeaways
- 3.6. Global Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By End-Users, 2019-2033
- 3.7. Global Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- 3.7.1. Hospitals
-
- 3.7.1.1. Insights
- 3.7.1.2. Key Takeaways
-
- 3.7.2. Specialty Clinics
- 3.7.2.1. Insights
- 3.7.2.2. Key Takeaways
- 3.7.3. Homecare
- 3.7.3.1. Insights
- 3.7.3.2. Key Takeaways
- 3.7.4. Others
- 3.7.4.1. Insights
- 3.7.4.2. Key Takeaways
- 3.7.1. Hospitals
- 4. Global Solid Tumor Therapeutics Market Analysis and Forecast, By Region, 2019-2033
- 4.1. Key Findings
- 4.2. Global Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Region, 2019-2033
- 4.2.1. North America
- 4.2.1.1. Regional Insights
- 4.2.2. Europe
- 4.2.2.1. Regional Insights
- 4.2.3. Asia Pacific
- 4.2.3.1. Regional Insights
- 4.2.4. Latin America
- 4.2.4.1. Regional Insights
- 4.2.5. Middle East & Africa
- 4.2.5.1. Regional Insights
- 4.2.1. North America
- 4.3. Global Solid Tumor Therapeutics Market Attractiveness Analysis, By Region
- 5. North America Solid Tumor Therapeutics Market Analysis and Forecast, 2019-2033
- 5.1. Key Findings
- 5.2. North America Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Therapy Type, 2019-2033
- 5.3. North America Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- 5.4. North America Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, Route of Administration, 2019-2033
- 5.5. North America Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- 5.6. North America Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By End-Users, 2019-2033
- 5.7. North America Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- 5.8. North America Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Country, 2019-2033
- 5.9. North America Solid Tumor Therapeutics Market Attractiveness Analysis, By Country
- 5.9.1. The US
- 5.9.2. Canada
- 6. Europe Solid Tumor Therapeutics Market Analysis and Forecast, 2019-2033
- 6.1. Key Findings
- 6.2. Europe Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Therapy Type, 2019-2033
- 6.3. Europe Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- 6.4. Europe Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, Route of Administration, 2019-2033
- 6.5. Europe Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- 6.6. Europe Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By End-Users, 2019-2033
- 6.7. Europe Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- 6.8. Europe Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Country, 2019-2033
- 6.9. Europe Solid Tumor Therapeutics Market Attractiveness Analysis, By Country
- 6.9.1. Germany
- 6.9.2. The UK
- 6.9.3. France
- 6.9.4. Spain
- 6.9.5. Italy
- 6.9.6. Russia
- 6.9.7. Netherland
- 6.9.8. Rest of Europe
- 7. Asia Pacific Solid Tumor Therapeutics Market Analysis and Forecast, 2019-2033
- 7.1. Key Findings
- 7.2. Asia Pacific Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Therapy Type, 2019-2033
- 7.3. Asia Pacific Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- 7.4. Asia Pacific Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, Route of Administration, 2019-2033
- 7.5. Asia Pacific Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- 7.6. Asia Pacific Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By End-Users, 2019-2033
- 7.7. Asia Pacific Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- 7.8. Asia Pacific Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Country, 2019-2033
- 7.9. Asia Pacific Solid Tumor Therapeutics Market Attractiveness Analysis, By Country
- 7.9.1. China
- 7.9.2. Japan
- 7.9.3. South Korea
- 7.9.4. India
- 7.9.5. Australia
- 7.9.6. New Zealand
- 7.9.7. Singapore
- 7.9.8. Thailand
- 7.9.9. Vietnam
- 7.9.10. Rest of Asia Pacific
- 8. Latin America Solid Tumor Therapeutics Market Analysis and Forecast, 2019-2033
- 8.1. Key Findings
- 8.2. Latin America Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Therapy Type, 2019-2033
- 8.3. Latin America Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- 8.4. Latin America Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, Route of Administration, 2019-2033
- 8.5. Latin America Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- 8.6. Latin America Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By End-Users, 2019-2033
- 8.7. Latin America Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- 8.8. Latin America Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Country, 2019-2033
- 8.9. Latin America Solid Tumor Therapeutics Market Attractiveness Analysis, By Country
- 8.9.1. Brazil
- 8.9.2. Mexico
- 8.9.3. Rest of Latin America
- 9. Middle East & Africa Solid Tumor Therapeutics Market Analysis and Forecast, 2019-2033
- 9.1. Key Findings
- 9.2. Middle East & Africa Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Therapy Type, 2019-2033
- 9.3. Middle East & Africa Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- 9.4. Middle East & Africa Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, Route of Administration, 2019-2033
- 9.5. Middle East & Africa Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- 9.6. Middle East & Africa Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By End-Users, 2019-2033
- 9.7. Middle East & Africa Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- 9.8. Middle East & Africa Solid Tumor Therapeutics Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Country, 2019-2033
- 9.9. Middle East & Africa Solid Tumor Therapeutics Market Attractiveness Analysis, By Country
- 9.9.1. South Africa
- 9.9.2. Saudi Arabia
- 9.9.3. UAE
- 9.9.4. Rest of Middle East & Africa
- 10. Competitive Landscape & Company Profiles
- 10.1. Market Competition Scenario Analysis, By Company
- 10.1.1. Key Takeaways
- 10.2. Overview of Major Market Players
- 10.3. Competitor Landscape
- 10.4. Strategic Mapping
- 10.5. Company Life Cycle Analysis
- 10.6. Company Market Share Analysis
- 10.7. Company Profiles
- 10.7.1. F. Hoffmann-La Roche Ltd
- 10.7.1.1. Company Details
- 10.7.1.2. Business Overview
- 10.7.1.3. Product Portfolio
- 10.7.1.4. Financial Insights
- 10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.1.6. SWOT Analysis
- 10.7.1.7. Geographic Footprint
- 10.7.2. Mylan N.V.
- 10.7.2.1. Company Details
- 10.7.2.2. Business Overview
- 10.7.2.3. Product Portfolio
- 10.7.2.4. Financial Insights
- 10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.2.6. SWOT Analysis
- 10.7.2.7. Geographic Footprint
- 10.7.3. Teva Pharmaceutical Industries Ltd.
- 10.7.3.1. Company Details
- 10.7.3.2. Business Overview
- 10.7.3.3. Product Portfolio
- 10.7.3.4. Financial Insights
- 10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.3.6. SWOT Analysis
- 10.7.3.7. Geographic Footprint
- 10.7.4. Sanofi
- 10.7.4.1. Company Details
- 10.7.4.2. Business Overview
- 10.7.4.3. Product Portfolio
- 10.7.4.4. Financial Insights
- 10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.4.6. SWOT Analysis
- 10.7.4.7. Geographic Footprint
- 10.7.5. Pfizer Inc.
- 10.7.5.1. Company Details
- 10.7.5.2. Business Overview
- 10.7.5.3. Product Portfolio
- 10.7.5.4. Financial Insights
- 10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.5.6. SWOT Analysis
- 10.7.5.7. Geographic Footprint
- 10.7.6. GlaxoSmithKline plc
- 10.7.6.1. Company Details
- 10.7.6.2. Business Overview
- 10.7.6.3. Product Portfolio
- 10.7.6.4. Financial Insights
- 10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.6.6. SWOT Analysis
- 10.7.6.7. Geographic Footprint
- 10.7.7. Novartis AG
- 10.7.7.1. Company Details
- 10.7.7.2. Business Overview
- 10.7.7.3. Product Portfolio
- 10.7.7.4. Financial Insights
- 10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.7.6. SWOT Analysis
- 10.7.7.7. Geographic Footprint
- 10.7.8. Merck & Co., Inc.
- 10.7.8.1. Company Details
- 10.7.8.2. Business Overview
- 10.7.8.3. Product Portfolio
- 10.7.8.4. Financial Insights
- 10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.8.6. SWOT Analysis
- 10.7.8.7. Geographic Footprint
- 10.7.9. Allergan
- 10.7.9.1. Company Details
- 10.7.9.2. Business Overview
- 10.7.9.3. Product Portfolio
- 10.7.9.4. Financial Insights
- 10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.9.6. SWOT Analysis
- 10.7.9.7. Geographic Footprint
- 10.7.10. Johnson & Johnson Private Limited
- 10.7.10.1. Company Details
- 10.7.10.2. Business Overview
- 10.7.10.3. Product Portfolio
- 10.7.10.4. Financial Insights
- 10.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.10.6. SWOT Analysis
- 10.7.10.7. Geographic Footprint
- 10.7.11. Hikma Pharmaceuticals PLC
- 10.7.11.1. Company Details
- 10.7.11.2. Business Overview
- 10.7.11.3. Product Portfolio
- 10.7.11.4. Financial Insights
- 10.7.11.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.11.6. SWOT Analysis
- 10.7.11.7. Geographic Footprint
- 10.7.12. Bristol-Myers Squibb Company
- 10.7.12.1. Company Details
- 10.7.12.2. Business Overview
- 10.7.12.3. Product Portfolio
- 10.7.12.4. Financial Insights
- 10.7.12.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.12.6. SWOT Analysis
- 10.7.12.7. Geographic Footprint
- 10.7.13. Bayer AG
- 10.7.13.1. Company Details
- 10.7.13.2. Business Overview
- 10.7.13.3. Product Portfolio
- 10.7.13.4. Financial Insights
- 10.7.13.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
- 10.7.13.6. SWOT Analysis
- 10.7.13.7. Geographic Footprint
- 10.7.1. F. Hoffmann-La Roche Ltd
- 10.1. Market Competition Scenario Analysis, By Company
- 11. Methodology and Data Source
- 11.1. Methodology/Research Approach
- 11.2. Market Size Estimation
- 11.3. Market Breakdown and Data Triangulation
- 11.4. Data Source
- 11.5. Secondary Sources
- 11.6. Primary Sources
- 11.7. Appendix
- 11.8. Disclaimer
- List of Tables
- Table 1. Global Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 2. Global Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 3. Global Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 4. Global Solid Tumor Therapeutics Market Value (US$ Bn), By Region, 2019-2033
- Table 5. North America Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 6. North America Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 7. North America Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 8. North America Solid Tumor Therapeutics Market Value (US$ Bn), By Country, 2019-2033
- Table 9. The US Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 10. The US Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 11. The US Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 12. Canada Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 13. Canada Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 14. Canada Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 15. Europe Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 16. Europe Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 17. Europe Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 18. Europe Solid Tumor Therapeutics Market Value (US$ Bn), By Country, 2019-2033
- Table 19. Germany Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 20. Germany Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 21. Germany Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 22. The UK Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 23. The UK Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 24. The UK Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 25. France Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 26. France Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 27. France Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 28. Spain Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 29. Spain Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 30. Spain Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 31. Italy Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 32. Italy Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 33. Italy Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 34. Russia Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 35. Russia Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 36. Russia Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 37. Netherland Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 38. Netherland Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 39. Netherland Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 40. Rest of Europe Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 41. Rest of Europe Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 42. Rest of Europe Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 43. Asia Pacific Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 44. Asia Pacific Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 45. Asia Pacific Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 46. Asia Pacific Solid Tumor Therapeutics Market Value (US$ Bn), By Country, 2019-2033
- Table 47. China Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 48. China Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 49. China Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 50. India Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 51. India Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 52. India Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 53. Japan Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 54. Japan Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 55. Japan Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 56. South Korea Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 57. South Korea Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 58. South Korea Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 59. Australia Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 60. Australia Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 61. Australia Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 62. New Zealand Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 63. New Zealand Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 64. New Zealand Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 65. Singapore Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 66. Singapore Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 67. Singapore Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 68. Thailand Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 69. Thailand Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 70. Thailand Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 71. Vietnam Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 72. Vietnam Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 73. Vietnam Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 74. Rest of Asia Pacific Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 75. Rest of Asia Pacific Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 76. Rest of Asia Pacific Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 77. Latin America Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 78. Latin America Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 79. Latin America Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 80. Latin America Solid Tumor Therapeutics Market Value (US$ Bn), By Country, 2019-2033
- Table 81. Brazil Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 82. Brazil Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 83. Brazil Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 84. Mexico Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 85. Mexico Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 86. Mexico Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 87. Rest of Latin America Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 88. Rest of Latin America Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 89. Rest of Latin America Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 90. Middle East & Africa Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 91. Middle East & Africa Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 92. Middle East & Africa Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 93. Middle East & Africa Solid Tumor Therapeutics Market Value (US$ Bn), By Country, 2019-2033
- Table 94. South Africa Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 95. South Africa Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 96. South Africa Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 97. Saudi Arabia Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 98. Saudi Arabia Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 99. Saudi Arabia Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 100. UAE Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 101. UAE Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 102. UAE Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- Table 103. Rest of Middle East & Africa Solid Tumor Therapeutics Market Value (US$ Bn), By Therapy Type, 2019-2033
- Table 104. Rest of Middle East & Africa Solid Tumor Therapeutics Market Value (US$ Bn), Route of Administration, 2019-2033
- Table 105. Rest of Middle East & Africa Solid Tumor Therapeutics Market Value (US$ Bn), By End-Users, 2019-2033
- List of Figures
- Figure 1. Global Solid Tumor Therapeutics Market Snapshot: Market Value (US$ Bn), 2019-2033
- Figure 2. Opportunity Map
- Figure 3. Opportunity Orbit
- Figure 4. Regional Market Share and BPS Analysis in Solid Tumor Therapeutics Market
- Figure 5. Global Solid Tumor Therapeutics Market Analysis, By Therapy Type, 2019, 2023 and 2033
- Figure 6. Global Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- Figure 7. Global Solid Tumor Therapeutics Market Analysis, Route of Administration, 2019, 2023 and 2033
- Figure 8. Global Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- Figure 9. Global Solid Tumor Therapeutics Market Analysis, By End-Users, 2019, 2023 and 2033
- Figure 10. Global Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- Figure 11. Global Solid Tumor Therapeutics Market Analysis, By Region, 2019, 2023 and 2033
- Figure 12. Global Solid Tumor Therapeutics Market Attractiveness Analysis, By Region
- Figure 13. North America Solid Tumor Therapeutics Market Analysis, By Therapy Type, 2019, 2023 and 2033
- Figure 14. North America Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- Figure 15. North America Solid Tumor Therapeutics Market (US$ Bn), by Chemotherapy, 2019-2033
- Figure 16. North America Solid Tumor Therapeutics Market (US$ Bn), by Immunotherapy, 2019-2033
- Figure 17. North America Solid Tumor Therapeutics Market (US$ Bn), by Targeted Therapy, 2019-2033
- Figure 18. North America Solid Tumor Therapeutics Market (US$ Bn), by Tyrosine kinase inhibitors, 2019-2033
- Figure 19. North America Solid Tumor Therapeutics Market (US$ Bn), by Proteasome Inhibitor, 2019-2033
- Figure 20. North America Solid Tumor Therapeutics Market (US$ Bn), by Hedgehog Pathway Inhibitor, 2019-2033
- Figure 21. North America Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 22. North America Solid Tumor Therapeutics Market Analysis, Route of Administration, 2019, 2023 and 2033
- Figure 23. North America Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- Figure 24. North America Solid Tumor Therapeutics Market (US$ Bn), by Oral, 2019-2033
- Figure 25. North America Solid Tumor Therapeutics Market (US$ Bn), by Parenteral, 2019-2033
- Figure 26. North America Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 27. North America Solid Tumor Therapeutics Market Analysis, By End-Users, 2019, 2023 and 2033
- Figure 28. North America Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- Figure 29. North America Solid Tumor Therapeutics Market (US$ Bn), by Hospitals, 2019-2033
- Figure 30. North America Solid Tumor Therapeutics Market (US$ Bn), by Specialty Clinics, 2019-2033
- Figure 31. North America Solid Tumor Therapeutics Market (US$ Bn), by Homecare, 2019-2033
- Figure 32. North America Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 33. North America Solid Tumor Therapeutics Market Analysis, By Country, 2019, 2023 and 2033
- Figure 34. North America Solid Tumor Therapeutics Market Attractiveness Analysis, By Country
- Figure 35. Europe Solid Tumor Therapeutics Market Analysis, By Therapy Type, 2019, 2023 and 2033
- Figure 36. Europe Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- Figure 37. Europe Solid Tumor Therapeutics Market (US$ Bn), by Chemotherapy, 2019-2033
- Figure 38. Europe Solid Tumor Therapeutics Market (US$ Bn), by Immunotherapy, 2019-2033
- Figure 39. Europe Solid Tumor Therapeutics Market (US$ Bn), by Targeted Therapy, 2019-2033
- Figure 40. Europe Solid Tumor Therapeutics Market (US$ Bn), by Tyrosine kinase inhibitors, 2019-2033
- Figure 41. Europe Solid Tumor Therapeutics Market (US$ Bn), by Proteasome Inhibitor, 2019-2033
- Figure 42. Europe Solid Tumor Therapeutics Market (US$ Bn), by Hedgehog Pathway Inhibitor, 2019-2033
- Figure 43. Europe Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 44. Europe Solid Tumor Therapeutics Market Analysis, Route of Administration, 2019, 2023 and 2033
- Figure 45. Europe Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- Figure 46. Europe Solid Tumor Therapeutics Market (US$ Bn), by Oral, 2019-2033
- Figure 47. Europe Solid Tumor Therapeutics Market (US$ Bn), by Parenteral, 2019-2033
- Figure 48. Europe Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 49. Europe Solid Tumor Therapeutics Market Analysis, By End-Users, 2019, 2023 and 2033
- Figure 50. Europe Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- Figure 51. Europe Solid Tumor Therapeutics Market (US$ Bn), by Hospitals, 2019-2033
- Figure 52. Europe Solid Tumor Therapeutics Market (US$ Bn), by Specialty Clinics, 2019-2033
- Figure 53. Europe Solid Tumor Therapeutics Market (US$ Bn), by Homecare, 2019-2033
- Figure 54. Europe Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 55. Europe Solid Tumor Therapeutics Market Analysis, By Country, 2019, 2023 and 2033
- Figure 56. Europe Solid Tumor Therapeutics Market Attractiveness Analysis, By Country
- Figure 57. Asia Pacific Solid Tumor Therapeutics Market Analysis, By Therapy Type, 2019, 2023 and 2033
- Figure 58. Asia Pacific Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- Figure 59. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Chemotherapy, 2019-2033
- Figure 60. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Immunotherapy, 2019-2033
- Figure 61. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Targeted Therapy, 2019-2033
- Figure 62. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Tyrosine kinase inhibitors, 2019-2033
- Figure 63. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Proteasome Inhibitor, 2019-2033
- Figure 64. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Hedgehog Pathway Inhibitor, 2019-2033
- Figure 65. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 66. Asia Pacific Solid Tumor Therapeutics Market Analysis, Route of Administration, 2019, 2023 and 2033
- Figure 67. Asia Pacific Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- Figure 68. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Oral, 2019-2033
- Figure 69. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Parenteral, 2019-2033
- Figure 70. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 71. Asia Pacific Solid Tumor Therapeutics Market Analysis, By End-Users, 2019, 2023 and 2033
- Figure 72. Asia Pacific Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- Figure 73. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Hospitals, 2019-2033
- Figure 74. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Specialty Clinics, 2019-2033
- Figure 75. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Homecare, 2019-2033
- Figure 76. Asia Pacific Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 77. Asia Pacific Solid Tumor Therapeutics Market Analysis, By Country, 2019, 2023 and 2033
- Figure 78. Asia Pacific Solid Tumor Therapeutics Market Attractiveness Analysis, By Country
- Figure 79. Latin America Solid Tumor Therapeutics Market Analysis, By Therapy Type, 2019, 2023 and 2033
- Figure 80. Latin America Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- Figure 81. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Chemotherapy, 2019-2033
- Figure 82. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Immunotherapy, 2019-2033
- Figure 83. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Targeted Therapy, 2019-2033
- Figure 84. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Tyrosine kinase inhibitors, 2019-2033
- Figure 85. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Proteasome Inhibitor, 2019-2033
- Figure 86. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Hedgehog Pathway Inhibitor, 2019-2033
- Figure 87. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 88. Latin America Solid Tumor Therapeutics Market Analysis, Route of Administration, 2019, 2023 and 2033
- Figure 89. Latin America Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- Figure 90. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Oral, 2019-2033
- Figure 91. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Parenteral, 2019-2033
- Figure 92. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 93. Latin America Solid Tumor Therapeutics Market Analysis, By End-Users, 2019, 2023 and 2033
- Figure 94. Latin America Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- Figure 95. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Hospitals, 2019-2033
- Figure 96. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Specialty Clinics, 2019-2033
- Figure 97. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Homecare, 2019-2033
- Figure 98. Latin America Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 99. Latin America Solid Tumor Therapeutics Market Analysis, By Country, 2019, 2023 and 2033
- Figure 100. Latin America Solid Tumor Therapeutics Market Attractiveness Analysis, By Country
- Figure 101. Middle East & Africa Solid Tumor Therapeutics Market Analysis, By Therapy Type, 2019, 2023 and 2033
- Figure 102. Middle East & Africa Solid Tumor Therapeutics Market Attractiveness Analysis, By Therapy Type
- Figure 103. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Chemotherapy, 2019-2033
- Figure 104. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Immunotherapy, 2019-2033
- Figure 105. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Targeted Therapy, 2019-2033
- Figure 106. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Tyrosine kinase inhibitors, 2019-2033
- Figure 107. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Proteasome Inhibitor, 2019-2033
- Figure 108. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Hedgehog Pathway Inhibitor, 2019-2033
- Figure 109. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 110. Middle East & Africa Solid Tumor Therapeutics Market Analysis, Route of Administration, 2019, 2023 and 2033
- Figure 111. Middle East & Africa Solid Tumor Therapeutics Market Attractiveness Analysis, Route of Administration
- Figure 112. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Oral, 2019-2033
- Figure 113. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Parenteral, 2019-2033
- Figure 114. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 115. Middle East & Africa Solid Tumor Therapeutics Market Analysis, By End-Users, 2019, 2023 and 2033
- Figure 116. Middle East & Africa Solid Tumor Therapeutics Market Attractiveness Analysis, By End-Users
- Figure 117. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Hospitals, 2019-2033
- Figure 118. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Specialty Clinics, 2019-2033
- Figure 119. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Homecare, 2019-2033
- Figure 120. Middle East & Africa Solid Tumor Therapeutics Market (US$ Bn), by Others, 2019-2033
- Figure 121. Middle East & Africa Solid Tumor Therapeutics Market Analysis, By Country, 2019, 2023 and 2033
- Figure 122. Middle East & Africa Solid Tumor Therapeutics Market Attractiveness Analysis, By Country
- 1. Executive Summary
-
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd. Company Profile
- Sanofi Company Profile
- Pfizer Inc Company Profile
- GlaxoSmithKline plc
- Novartis AG Company Profile
- Merck & Co. Inc.
- Allergan
- AstraZeneca Plc Company Profile
- Johnson & Johnson Private Limited
- Hikma Pharmaceuticals PLC
- Bristol-Myers Squibb Company
- Bayer AG Company Profile
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |